Orforglipron
![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C48H48F2N10O5 |
Molar mass | 882.974 g·mol−1 |
3D model (JSmol) | |
| |
|
Orforglipron (LY-3502970) is an oral, non-peptide, small molecule glucagon-like peptide-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company.[1][2] It is easier to produce than current peptide GLP-1 agonists and is expected to be cheaper.[3]
See also
[edit]References
[edit]- ^ Pratt E, Ma X, Liu R, Robins D, Coskun T, Sloop KW, et al. (June 2023). "Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes". Diabetes, Obesity & Metabolism. 25 (9): 2642–2649. doi:10.1111/dom.15150. PMID 37264711. S2CID 259022851.
- ^ Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, et al. (June 2023). "Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity". The New England Journal of Medicine. 389 (10): 877–888. doi:10.1056/NEJMoa2302392. PMID 37351564.
- ^ Sidik, Saima (2023). "Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective". Nature. 619 (7968): 19. Bibcode:2023Natur.619...19S. doi:10.1038/d41586-023-02092-9. PMID 37369789.